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Background: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus 
(SLE). Activation of complement system which leads to the production of C4 and its 
ultimate product, C4d, plays an important role in the pathogenesis of LN. 
Objectives: Although serum C4d levels correlate with disease activity, there is almost no 
study on the correlation between tissue deposition of C4d and classes of LN.
Patients and Methods: Seventy-two patients with a diagnosis of SLE who met ≥ 4 criteria 
of American Rheumatism Association (ARA) were enrolled in this study. Blood levels 
of anti-nuclear antigens (ANA), anti-double stranded DNA (Anti-dsDNA), C3, C4 and 
antiphospholipid antibodies were measured. Renal tissue obtained by biopsy was examined 
regarding diffuse granular deposition of C4d along the glomerular capillary loops and 
classes of LN according to the World Health Organization (WHO) classification.
Results: LN class IV was the most prevalent and LN class I had the least prevalence. There 
was no correlation between positive C4d staining and classes of LN (P > 0.05), but a 
significant correlation between positive Anti-dsDNA and C4d positive LN was found 
(P = 0.05). Likewise no correlation was detected between the low levels of complements 
and classes of LN or C4d positivity.
Conclusions: The presence of C4d indicates activation of classical complement pathway in 
LN. C4d deposition in glomerular capillaries of LN does not indicate the present disease 
activity but may be a useful marker to predict the prognosis of LN. Anti-dsDNA is a 
valuable test for disease activity and is correlated with C4d positive staining.
ABSTRACT
Implication for health policy/practice/research/medical education:
In a study on 72 patients with a diagnosis of  SLE, we found anti-dsDNA is a valuable test in disease activity and is correlated 
with C4d positive staining.
Please cite this paper as: Malakoutian T, Amouzegar A, Asgari M, Shooshtarizadeh T. C4d in lupus nephritis and correlation with 
clinicopathologic findings. J Nephropathol. 2018;7(3):166-170. DOI: 10.15171/jnp.2018.36.
1. Background
Systemic Lupus Erythematosus (SLE) is an autoimmune 
multisystem disease, mediated by autoantibodies directed 
against nuclear antigens (ANA) and particularly against 
DNA (Anti-dsDNA), and immune complexes (1,2). The 
overall incidence of  SLE ranges from 1.8 to 7.6 cases per 
100 000 (2). 
Antiphospholipid syndrome (APS) is an acquired auto-
antibody mediated condition characterized by frequent 
arterial or venous thrombosis and/or pregnancy 
morbidity. APS may occur primarily or in association 
with any other autoimmune diseases. The major auto 
antibodies detected in these patients are directed against 
phospholipid (PL) binding plasma proteins, mostly 
against β2 glycoprotein I (anti-β2GPI), cardiolipin, and 
prothrombin (1).
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Lupus nephritis (LN) is a serious complication of  SLE. 
Approximately 25% to 50% of  lupus patients have 
clinical renal disease at onset, and as many as 60% 
of  adults with SLE develop renal disease during their 
course (3). 
Complement system has an important role in the 
pathogenesis of  LN (4). In recent years, the potential 
importance of  C4d, an ultimate product of  complement 
C4 activation has been revealed in the pathogenesis 
of  SLE (5). C4d binds to endothelial cell surfaces and 
the extracellular matrix material of  vascular basement 
membranes (6). C4d deposition on endothelial cells 
induces insertion of  membrane attack complex (MAC), 
which is followed by Von Willebrand factor release from 
endothelial cells, and then platelet aggregation (6). The 
presence of  C4d and C1q deposits with C3 deposits 
in the glomerulus is considered to be the evidence 
for the activation of  the classical pathway (7). In LN, 
diffuse granular deposition of  C4d along the glomerular 
capillary loops is seen (8).
During past years, the presence of  hypocomplementemia 
and high titer of  anti-double stranded DNA (anti-
dsDNA) in serum have been used for diagnosis of 
disease activity in SLE (1). Recently, other markers such 
as serum and tissue C4d seem to have important roles 
in the determination of  lupus activity (9) and it seems 
that complement derivative products are more sensitive 
indicator of  disease activity compared to the usual 
measurement of  serum C3 and C4 (10-17).
2. Objectives
Although serum C4d levels correlate with disease activity 
(9), there is almost no study on the correlation between 
tissue deposition of  C4d and classes of  LN.
Moreover C4d is one of  the main pathologic parameters 
to identify antibody-mediated rejection (18) but the 
importance of  deposition of  C4d in LN has been 
remained unclear.
Due to lack of  comprehensive study in this regard, 
this study is designed to determine the incidence of 
tissue C4d deposition in LN and the importance of  its 
detection in different classes of  LN and correlation with 
clinicopathologic findings. This is important as many of 
the previously designated laboratory measurements do 
not accurately disclose this relation.
3. Patients and Methods 
3.1. Study population
This study was carried out in the nephrology department 
of  Hasheminejad hospital in Tehran, Iran, from 2012 
to 2013All cases were provided written informed 
consent before study registration. The diagnosis of 
SLE was established by the presence of  certain clinical 
and laboratory features defined by the 1997 modified 
American Rheumatism Association (ARA) criteria (2). 
An increase in serum levels of  anti-ds DNA and decrease 
in serum complement levels was used as an indicator 
of  SLE activity. APS was defined based on laboratory 
findings including either abnormal anticardiolipin 
(aCL) Abs (IgM and IgG) and β2GP1 (IgG, IgM) or 
abnormal antiphospholipid antibodies (aPL antibodies) 
(IgM and IgG), β2GP1 (IgG, IgM), and low C3 and C4 
levels. LN was classified according to the World Health 
Organization (WHO) into six classes (9) and lesions 
limited to the renal mesangium (LN II) were considered 
as less severe, while diffuse disease (LN IV) was a 
criterion of  most severe disease (3).
Estimated glomerular filtration rate (eGFR) was 
calculated based on creatinine clearance (CrCl) using the 
Cockcroft and Gault formula (19). The GFR of  ≤ 60 
mL/min was considered abnormal.
Demographic data, history of  arterial or venous 
thrombosis in both sex, miscarriage and other pregnancy 
complications in females were recorded. 
3.3. Study design 
Blood levels of  ANA, anti-double stranded DNA (Anti 
dsDNA), C3, C4, creatinine, aCL, aPL antibodies and 
anti β2 GP1 were measured and 24 hours urine was 
collected. For measurement of  aCL, aPL antibodies 
and anti β2 GP1, an AESKULISA ELISA kit was used. 
According to the kit package insert, a normal range for 
aCL, aPL antibodies and-anti β2 GP1 were showed in 
Table 1.
All patients underwent a renal biopsy and two samples 
were taken. One of  the tissue samples was fixed in 
10% formalin and then blocks were provided in 2-3 
millimeters sections for hematoxylin & eosin (H&E), 
periodic acid–Schiff  (PAS), silver methenamine and 
Masson’s trichrome staining. The prepared sections were 
examined under light microscopy. The second sample 
was kept in normal saline and sections were prepared for 
immunofluorescence microscopic examination in which 
they were assessed for IgG, IgM, IgA, C1q, C3 and C4. 
All tissue samples were stained for C4d deposition and 
reported as C4d positive, if  there was diffuse granular 
deposition of  C4d along the glomerular capillary loops 
and peritubular capillaries C4d deposition, or C4d 
negative.
3.3. Ethical issues
1) The research followed the tenets of  the Declaration of 
Malakoutian M et al
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Helsinki; 2) informed consent was obtained; and 3) This 
study was approved by the Ethics Committee of  Iran 
University of  Medical Sciences (ethical code# 93-02-
30-24471). This study was conducted as the nephrology 
fellowship thesis of  Atefeh Amouzegar in Iran University 
of  Medical Sciences, Tehran, Iran.
3.4. Statistical analysis
Statistical analysis was performed using SPSS® 18 
Software. Continuous variables in each group of  subjects 
were stated as mean values ± standard deviation (SD). 
Differences between mean of  two groups were done 
using the unpaired Student’s t test and Mann–Whitney 
U-test for variables with normal and non-normal 
distributions, respectively. Chi-square and Fischer’s exact 
tests to compare dichotomous variable were employed. 
In all cases, a P value of  less than 0.05 was considered to 
be statistically significant.
4. Results 
4.1. Patients’ characteristics
Seventy-two patients with the diagnosis of  SLE who 
met ≥ 4 criteria of  ARA were enrolled in this study (2). 
All patients were new cases of  SLE. Fifty-eight (80.6%) 
patients were female and 14 (19.4%) patients were male. 
The mean age of  patients was 29.83 ± 10.47 years (mean 
± SD), with a mean age of  29.86 ± 11.36 years in females 
and 30.68 ± 9.48 years in males.
The mean systolic blood pressure was 120.53± 15.88 
mm Hg and the mean diastolic pressure was 75± 6.54 
mmHg. Twenty-four hours urine collection revealed that 
all patients had proteinuria. There were 7 miscarriages 
and 4 preeclampsia and one case of  thrombocytopenia 
but no case of  stillbirth in our female patients.
The duration of  disease was between 2 months and 20 
years with a mean of  29.63 months (2.5 years). The mean 
plasma creatinine level was 2.51± 2.71 mg/dL, mean 
Table 1. The values for disease defining tests and patient values
Normal value Patient % with abnormal levels
aCL IgG 8-12 4 (10%)
aCL IgM 8-12 0 (0%)
Anti-β2GP1 IgG 8-12 1 (2.8%)
Anti-β2GP1 IgM 8-12 1 (2.8%)
C3 0.89-1.87 35 (71%)
C4 0.165-0.38 31 (62%)
ANA 1-12 9 (18.75%)
Anti-dsDNA 8-12 51 (71.70%)
aCL: anticardiolipin; β2GP1: Beta 2 glycoprotein complex 1; ANA: anti-
nuclear antibody;  Anti-dsDNA: Anti-double stranded DNA.
Table 2. Frequency of  different classes of  lupus nephritis
LN class Number of  patients Percent
LN 1 0 0
LN 2 4 15.6%
LN 3 13 18%
LN 4 42 58.3%
LN 5 12 16.7%
LN 6 1 3.4%
Total 72 100
LN: lupus nephritis.
body weight (BW) was 64.69± 11.94 kg and mean GFR 
with the use of  C-G formula was 61± 34.54 mm/min. 
Around 49.2 % had low and 50.8% had normal GFR.
The incidence of  APS was 20% (CI; 95%). In this 
study all 72 patients underwent renal biopsy and LN 
was categorized for them according to the WHO 
classification. C4d staining was successfully done in 47 
patients. Twenty-seven cases (57.4%) had positive C4d 
staining and 20 cases (42.6%) had negative results. No 
glomerular microthrombosis (GMT) was reported in 
biopsy samples.
LN class 4 was the most prevalent which was seen in 42 
patients (58.3%) and LN class 1 had the least prevalence. 
(Table 2). There was no correlation between C4d positive 
LN and different classes of  LN (CI; 95%). We did not 
find any positive correlation between positive ANA or 
anti-dsDNA tests and classes of  LN (P > 0.05). However, 
we found a significant correlation between positive anti 
dsDNA and C4d positive LN (P = 0.05). There was 
also no positive relation between APS and positive C4d 
staining (P = 0.47).
Likewise we did not find any correlation between the 
low levels of  complements and classes of  LN or C4d 
positivity (P > 0.05). 
5. Discussion 
We observed a positive correlation between anti-dsDNA 
positivity, which is one of  the parameters of  LN activity 
and C4d positive staining. This finding shows that 
activation of  the classical pathway of  complement has a 
crucial pathogenic role in activation or flare of  LN.
In the group of  patients enrolled in this study we did 
not find any correlation between the intensity of  C4d 
staining and different classes of  LN.
In the normal kidney, the glomerular mesangium and 
GBM are stained for C4d in a granular and segmental 
pattern and the wall of  some renal arterioles stain in a 
linear pattern (20). However, in LN, diffuse granular 
deposition of  C4d along the glomerular capillary loops 
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and peritubular capillaries are seen (8). The presence of 
C4d and C1q deposits in combination with C3 deposits 
in the glomerulus is considered to be the evidence 
for the activation of  the classi cal pathway which has 
an important role in the pathogenesis of  LN (4,7). 
In the current study, the validity of  C4d staining by 
immunofluorescence method was evaluated as a useful 
marker of  different classes of  LN. Several studies have 
assessed the correlation between C4d staining and LN 
activity (18-21).
In a study by Shen et al the intensity of  glomerular C4d 
staining was strongly associated with the presence of  IgG 
anti-b2GPI antibodies (22), however we did not find any 
correlation between anti β2GP1 and C4d staining that 
could be due to small sample size.
In a study by Senaldi et al no correlation was found 
between reduced C4 levels and degrees of  disease activity 
(9). We also did not find any correlation between low 
complements level and classes of  LN and C4d staining.
Kim and Jeong et al studied glomerular C4d deposition 
in 21 cases diagnosed as LN. They found a correlation 
between the intensity of  C4d with those of  capillary IgG, 
IgA, C4, C1q, and fibrinogen but C4d staining intensity 
did not correlate with the LN activity index (8). We 
also did not find any correlation between the intensity 
of  C4d staining and classes of  LN. Furthermore, Sahin 
et al observed a relationship between glomerular C4d 
staining and activity of  LN (22). We also found a positive 
correlation between anti-dsDNA positivity, which is 
one of  the parameters of  LN activity and C4d positive 
staining but we did not find any correlation between C4d 
Positivity with classes of  LN.
In two studies conducted by Bheemavathi et al – which 
evaluated the patterns of  glomerular C4d deposition in 
patients with LN – and Kim and Jeong for the validity 
of  C4d staining as a marker of  LN activity, they did not 
find peritubular capillaries deposition of  C4d (8,18). We 
also did not find peritubular capillaries C4d deposition in 
our biopsy samples.
In the same study by Kim and Jeong, they found that 
C4d deposition could be a more sensitive marker of 
classical complement pathway activation but not a useful 
marker of  disease activity (8).
6. Conclusions
C4d positive indicates activation of  classical complement 
pathway in LN. C4d deposition in glomerular capillaries 
of  LN does not indicate the present disease activity but 
may be a useful marker to predict the prognosis of  LN. 
Anti-dsDNA is a valuable test for disease activity and is 
correlated with C4d positive staining.
Limitations of  the study
It would be more valuable to have a proper follow up to 
find valid associations between disease activity and C4d 
deposition. Moreover adequate sample size is required.
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